7 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 1 | Terminated 1 |
Follow Liver Failure, Acute: new trials by email Literature Review of Liver Failure, Acute trials Research Report on Liver Failure, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites | Phase 2 | Terminated | Genfit | 15 | 2023-07-02 | 2026-07-23 |
| TAK-242 in Patients With Acute Alcoholic Hepatitis TAK-242, Placebo - Acute-On-Chronic Liver Failure | Phase 2 | Terminated | Akaza Bioscience Ltd | 4 | 2020-11-12 | 2026-10-14 |
| Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF) HepaStem, Placebo - Acute on Chronic Liver Failure | Phase 2 | Terminated | Cellaion SA | 133 | 2020-01-21 | 2024-05-22 |
| Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure allo-APZ2-ACLF - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Terminated | RHEACELL GmbH & Co. KG | 5 | 2019-03-22 | 2021-11-17 |
| Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) ELAD - Acute Liver Failure, Fulminant Hepatic Failure | Phase 2 | Terminated | Vital Therapies, Inc. | 8 | 2014-10-01 | 2019-02-12 |
| Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF IDN-6556, Placebo - Acute on Chronic Hepatic Failure, Acute Liver Failure | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 23 | 2013-09-01 | 2016-04-11 |
Acute-On-Chronic Liver Failure (5) · Fibrosis (3) · Liver Failure (3) · Ascites (1) · Hepatic Encephalopathy (1) · Hepatitis, Alcoholic (1) · Kidney Diseases (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Renal Insufficiency (1) · Wounds and Injuries (1)
Digestive System Diseases (7) · Hepatic Insufficiency (7) · Liver Diseases (6) · Liver Failure (4) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Alcohol-Induced Disorders (1) · Alcohol-Related Disorders (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · Control Groups (1) · ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (1)
Genfit (2) · Akaza Bioscience Ltd (1) · Cellaion SA (1) · Conatus Pharmaceuticals Inc. (1) · RHEACELL GmbH & Co. KG (1) · Vital Therapies, Inc. (1)
United States (4) · France (3) · Germany (3) · Belgium (2) · Italy (2) · Spain (2) · United Kingdom (2) · Austria (1) · Bulgaria (1) · Denmark (1) · Estonia (1) · Georgia (1) · Hungary (1) · Latvia (1) · Lithuania (1)
Angel Alsina, MD (1) · David J Reich, MD (1) · Jan Stange, MD, Ph.D. (1) · Juan Gallegos-Orozco, MD (1) · Julie Thompson, MD (1) · Kalyan R Bhamidimarri, MD (1) · Lance Stein, MD (1) · Lewis W Teperman, MD (1) · Linda S Sher, MD (1) · Marquis Hart, MD (1) · Matthias Ebert, Prof. Dr. (1) · Nikolaos T Pyrsopoulos, MD (1) · Nikunj Shah, MD (1) · Parvez Mantry, MD (1)
2025 (1)